The susceptibility of 10 multiply antibiotic-resistant strains of Streptococcus pneumoniae to several quinoline antibiotics and to coumermycin, novobiocin, and penicillin was determined. The MIC of penicillin for all test isolates was .4 ,Ig/ml. Ciprofloxacin was the most active quinoline derivative tested, followed by norfloxacin.
These isolates of S. pneumoniae were not inhibited by the remaining quinolines at achievable concentrations in serum. Coumermycin and ciprofloxacin were the most active antibiotics tested in this study.
Resistance to penicillin of many isolates of Streptococcus pneumoniae from South Africa was reported in 1978 (4) . These isolates also were variably resistant to many other antibiotics such as ampicillin, cephalothin, erythromycin, and chloramphenicol. Recently, it was reported that the MICs of several new beta-lactam compounds for these isolates were 50-to 150-fold higher than those for penicillinsusceptible strains (6) . The mechanism of this resistance may be attributed to alteration of penicillin binding proteins of those selected strains (12) . Most of the reported patients with clinical disease have been seen in South Africa; however, sporadic cases have developed in several areas of the United States (11) .
A new class of structurally related compounds which are derivatives of nalidixic acid are currently undergoing laboratory and clinical trials. These substituted quinoline antibiotics are active against a broad range of gram-positive and gram-negative bacteria (1, 3, 8) . Ciprofloxacin and norfloxacin are two of these agents which have activity against a greater number of gram-positive and gram-negative organisms when compared with the activity of the other quinoline agents. Coumermycin is a bis-hydroxycoumerin compound that inhibits DNA synthesis and has been reported to be bactericidal at extremely low concentrations against grampositive species (7) . Novobiocin has a complex mechanism of action involving interference with cell wall synthesis and inhibition of protein and nucleic acid synthesis (5) . The antibacterial activity of novobiocin is greatest against grampositive organisms. The present study was undertaken to assess the comparative in vitro activity of these antibiotics against penicillin-resistant pneumococci.
Ten penicillin-resistant strains of S. pneumoniae (MIC, .4 p.g/ml) were tested in this study. These isolates were originally obtained from South Africa by Robert Austrian. The antibiotic susceptibilities of some of these strains have been reported previously (6 CFU of S. pneumoniae per ml was used, and the broth microdilution method was modified according to Thornsberry and Swenson (10) . The MIC was defined as the lowest concentration of antibiotic that produced no visible turbidity in microtiter wells after 24 h of incubation at 37°C. The MBC was defined as the lowest concentration of antibiotic which produced a .99.9% reduction of the initial inoculum. This value was determined by subculturing 0.015 ml of those dilutions which showed no visible growth after 24 h onto Mueller-Hinton agar plates supplemented with 5% sheep blood. Table 1 shows the MICs of various antibiotics for penicillin-resistant S. pneumoniae isolates. The MBCs of the antibiotics tested were equal to or one dilution lower than the MICs of the antibiotics against all isolates. Accordingly, only the MICs are reported. The MIC of penicillin was .4
,ug/ml against all isolates. Ciprofloxacin was the most active quinoline antibiotic in this test system, with all strains being inhibited by s1 ,ug of ciprofloxacin per ml. Norfloxacin was slightly less active than ciprofloxacin. The susceptibility of these isolates to WIN 35439 was comparable with the susceptibility to norfloxacin. The other quinoline derivatives, as well as nalidixic acid, were not effective in inhibiting the growth of these strains. The activity of coumermycin against these isolates was similar to that of ciprofloxacin, and these two antibiotics were the most active agents tested in this study. All strains were inhibited by -1 slg of coumermycin per ml. Novobiocin inhibited these isolates at concentrations of s2 ,ug/ml. Some new quinoline antibiotics are being developed for both oral and parenteral use. Their role in antimicrobial ANTIMICROB. AGENTS CHEMOTHER. chemotherapy has yet to be established, and ongoing clinical trials will help define this issue. Ciprofloxacin, in our study, was the most effective substituted quinoline against penicillin-resistant pneumococci. The average MBC of ciprofloxacin was one fifth or less than known mean peak concentrations of ciprofloxacin in serum after a 500-mg oral dose (2) . The MBCs of norfloxacin for the tested isolates were not dissimilar from achievable peak serum levels, and this may limit the use of this antibiotic for treating patients with pneumococcal infections (9) . There are few published data to show that the other quinoline antibiotics achieve therapeutic serum levels. Nalidixic acid also was ineffective against these isolates.
Coumermycin has been shown to be extremely active against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis (7) . Its clinical efficacy has not been established. In the present study coumermycin was bactericidal for the tested isolates at very low concentrations. The bactericidal efficacy of coumermycin was similar to that of ciprofloxacin. The clinical use of novobiocin is limited in modern antimicrobial therapy and is confined to the treatment of gram-positive bacterial infections. Peak serum levels are 10 to 20 times above that of the MBCs of novobiocin against the penicillin-resistant pneumococci used in this study (5 
